At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,674 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment Adherence to JNC 7(Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 7th Report) Guidelines in Cardiovascular (CV)-Risk Patients Across the Middle East - the Impact of Ramadan Fasting on Achieving Treatment Goals in Daily Practice
In Brief
An observational study for Hypertension. Completed, enrolled 1,674 participants across 132 sites in 5 countries.
Detailed Summary
This is an out-patient based prospective, multi-centre, observational post-marketing surveillance study amongst internists and cardiologists. In this study, patients with essential hypertension and at least one additional risk factor will be included. Patients may take any antihypertensive treatment which is approved for cardiovascular protection including Micardis 80 mg / Micardis Plus. Patients will be followed over one year in four visits from baseline to endpoint with an additional visit before and after the month of Ramadan.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesAlgeria, Egypt, Lebanon, Saudi Arabia, United Arab Emirates
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedMay 2013
Primary CompletionJul 2014
TodayJul 2026
First PostedMay 15, 2013
Enrollment StartOct 1, 2011
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.1 years ago